#AACR26 highlights #CommunityOnc:
Same topic zoldonrasib · 18 peopledaraxonrasibROS1#COMMUNITYONC#CM77T#TRUST#MEDXHeat 9369 likes1 reply23 reposts
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
zoldonrasib
18 people · 24 posts
Heat trend for this story
Heat now 1·Peak in the comparable set 1 (Apr 23 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted1
Heat over time
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
Records
| Drug / trial | Readout | Setting |
|---|---|---|
| zoldonrasibzoldonrasibRMC-9805 | ORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73% | G12D NSCLC · Phase 1 |
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
- Whether zoldonrasib’s response rate stays above 40% once the cohort is past 50 patients.
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Floor
x.com@Score6060 x.com@Score6060 KRAS G12D mutations remain an unmet need in #NSCLC.
MedPage Today@medpagetodayScore6060 Silas Inman@SilasInmanScore6060 Zoldonrasib Displays Early Safety, Efficacy in Pretreated KRAS G12D–Mutated NSCLC
Lung Cancers Today@Lung_CancersScore6060 Ben Fidler@BentheFidlerScore6060 ICYMI: #AACR26: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
cancer_navi@cancer_naviScore6060
Ben Fidler@BentheFidlerScore6060 AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Stephen V Liu, MD@StephenVLiuScore6060 Stephen V Liu, MD@StephenVLiuScore6060 Stephen V Liu, MD@StephenVLiuScore6060 Young Kwang Chae, MD, MPH, MBA@youngkwangchaeScore6060 Targeting the "undruggable" KRAS G12D just got a major boost at #AACR26!
Oncology Tube@oncologytubeScore6060 Paul H, PharmD, RPH@phsiao4Score6060 Arnav Mehta@arnavmehta3Score6060 Incredibly clean safety profile for Zoldonrasib (KRAS G12D)!
Anirban Maitra@Aiims1742Score6060 Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant #LungCancer
LUNGevity Foundation@LUNGevityScore6060 Oriol Mirallas MD@DrMirallasScore6060 LUNGevity Foundation@LUNGevityScore6060 Moffitt Cancer Center@MoffittNewsScore6060 Happening now at #AACR26 Clinical Trials Plenary: Jonathan Riess, MD (
Raffaele Di Giacomo, PhD@sciqstScore6060 AACR@AACRScore6060 AACR@AACRScore6060 Oncology Tube@oncologytubeScore6060